Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium

Daekee Lee, Ming Yu, Eunjung Lee, Hyunok Kim, Yanan D Yang, Kyoungmi Kim, Christina Pannicia, Jonathan M. Kurie, David W. Threadgill

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Pharmacologic blockade of EGFR or the closely related receptor ERBB2 has modest efficacy against colorectal cancers in the clinic. Although the upregulation of ERBB3, a pseudo-kinase member of the EGFR/ERBB family, is known to contribute to EGFR inhibitor resistance in other cancers, its functions in normal and malignant intestinal epithelium have not been defined. We have shown here that the intestinal epithelium of mice with intestine-specific genetic ablation of Erbb3 exhibits no cytological abnormalities but does exhibit loss of expression of ERBB4 and sensitivity to intestinal damage. By contrast, intestine-specific Erbb3 ablation resulted in almost complete absence of intestinal tumors in the ApcMin mouse model of colon cancer. Unlike nontransformed epithelium lacking ERBB3, intestinal tumors lacking ERBB3 had reduced PI3K/ AKT signaling, which led to attenuation of tumorigenesis via a tumor-specific increase in caspase-3-mediated apoptosis. Consistent with the mouse data, which suggest that ERBB3-ERBB4 heterodimers contribute to colon cancer survival, experimentally induced loss of ERBB3 in a KRAS mutant human colon cancer cell line was associated with loss of ERBB4 expression, and siRNA knockdown of either ERBB3 or ERBB4 resulted in elevated levels of apoptosis. These results indicate that the ERBB3 pseudo-kinase has essential roles in supporting intestinal tumorigenesis and suggest that ERBB3 may be a promising target for the treatment of colorectal cancers.

Original languageEnglish (US)
Pages (from-to)2702-2713
Number of pages12
JournalJournal of Clinical Investigation
Volume119
Issue number9
DOIs
StatePublished - Sep 1 2009
Externally publishedYes

Fingerprint

Intestinal Mucosa
Phosphotransferases
Colonic Neoplasms
Apoptosis
Intestines
Colorectal Neoplasms
Neoplasms
Carcinogenesis
Phosphatidylinositol 3-Kinases
Caspase 3
Small Interfering RNA
Up-Regulation
Epithelium
Cell Line
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. / Lee, Daekee; Yu, Ming; Lee, Eunjung; Kim, Hyunok; Yang, Yanan D; Kim, Kyoungmi; Pannicia, Christina; Kurie, Jonathan M.; Threadgill, David W.

In: Journal of Clinical Investigation, Vol. 119, No. 9, 01.09.2009, p. 2702-2713.

Research output: Contribution to journalArticle

Lee, D, Yu, M, Lee, E, Kim, H, Yang, YD, Kim, K, Pannicia, C, Kurie, JM & Threadgill, DW 2009, 'Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium', Journal of Clinical Investigation, vol. 119, no. 9, pp. 2702-2713. https://doi.org/10.1172/JCI36435
Lee, Daekee ; Yu, Ming ; Lee, Eunjung ; Kim, Hyunok ; Yang, Yanan D ; Kim, Kyoungmi ; Pannicia, Christina ; Kurie, Jonathan M. ; Threadgill, David W. / Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. In: Journal of Clinical Investigation. 2009 ; Vol. 119, No. 9. pp. 2702-2713.
@article{2cf216fb30334fada1739c6b614fa077,
title = "Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium",
abstract = "Pharmacologic blockade of EGFR or the closely related receptor ERBB2 has modest efficacy against colorectal cancers in the clinic. Although the upregulation of ERBB3, a pseudo-kinase member of the EGFR/ERBB family, is known to contribute to EGFR inhibitor resistance in other cancers, its functions in normal and malignant intestinal epithelium have not been defined. We have shown here that the intestinal epithelium of mice with intestine-specific genetic ablation of Erbb3 exhibits no cytological abnormalities but does exhibit loss of expression of ERBB4 and sensitivity to intestinal damage. By contrast, intestine-specific Erbb3 ablation resulted in almost complete absence of intestinal tumors in the ApcMin mouse model of colon cancer. Unlike nontransformed epithelium lacking ERBB3, intestinal tumors lacking ERBB3 had reduced PI3K/ AKT signaling, which led to attenuation of tumorigenesis via a tumor-specific increase in caspase-3-mediated apoptosis. Consistent with the mouse data, which suggest that ERBB3-ERBB4 heterodimers contribute to colon cancer survival, experimentally induced loss of ERBB3 in a KRAS mutant human colon cancer cell line was associated with loss of ERBB4 expression, and siRNA knockdown of either ERBB3 or ERBB4 resulted in elevated levels of apoptosis. These results indicate that the ERBB3 pseudo-kinase has essential roles in supporting intestinal tumorigenesis and suggest that ERBB3 may be a promising target for the treatment of colorectal cancers.",
author = "Daekee Lee and Ming Yu and Eunjung Lee and Hyunok Kim and Yang, {Yanan D} and Kyoungmi Kim and Christina Pannicia and Kurie, {Jonathan M.} and Threadgill, {David W.}",
year = "2009",
month = "9",
day = "1",
doi = "10.1172/JCI36435",
language = "English (US)",
volume = "119",
pages = "2702--2713",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "9",

}

TY - JOUR

T1 - Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium

AU - Lee, Daekee

AU - Yu, Ming

AU - Lee, Eunjung

AU - Kim, Hyunok

AU - Yang, Yanan D

AU - Kim, Kyoungmi

AU - Pannicia, Christina

AU - Kurie, Jonathan M.

AU - Threadgill, David W.

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Pharmacologic blockade of EGFR or the closely related receptor ERBB2 has modest efficacy against colorectal cancers in the clinic. Although the upregulation of ERBB3, a pseudo-kinase member of the EGFR/ERBB family, is known to contribute to EGFR inhibitor resistance in other cancers, its functions in normal and malignant intestinal epithelium have not been defined. We have shown here that the intestinal epithelium of mice with intestine-specific genetic ablation of Erbb3 exhibits no cytological abnormalities but does exhibit loss of expression of ERBB4 and sensitivity to intestinal damage. By contrast, intestine-specific Erbb3 ablation resulted in almost complete absence of intestinal tumors in the ApcMin mouse model of colon cancer. Unlike nontransformed epithelium lacking ERBB3, intestinal tumors lacking ERBB3 had reduced PI3K/ AKT signaling, which led to attenuation of tumorigenesis via a tumor-specific increase in caspase-3-mediated apoptosis. Consistent with the mouse data, which suggest that ERBB3-ERBB4 heterodimers contribute to colon cancer survival, experimentally induced loss of ERBB3 in a KRAS mutant human colon cancer cell line was associated with loss of ERBB4 expression, and siRNA knockdown of either ERBB3 or ERBB4 resulted in elevated levels of apoptosis. These results indicate that the ERBB3 pseudo-kinase has essential roles in supporting intestinal tumorigenesis and suggest that ERBB3 may be a promising target for the treatment of colorectal cancers.

AB - Pharmacologic blockade of EGFR or the closely related receptor ERBB2 has modest efficacy against colorectal cancers in the clinic. Although the upregulation of ERBB3, a pseudo-kinase member of the EGFR/ERBB family, is known to contribute to EGFR inhibitor resistance in other cancers, its functions in normal and malignant intestinal epithelium have not been defined. We have shown here that the intestinal epithelium of mice with intestine-specific genetic ablation of Erbb3 exhibits no cytological abnormalities but does exhibit loss of expression of ERBB4 and sensitivity to intestinal damage. By contrast, intestine-specific Erbb3 ablation resulted in almost complete absence of intestinal tumors in the ApcMin mouse model of colon cancer. Unlike nontransformed epithelium lacking ERBB3, intestinal tumors lacking ERBB3 had reduced PI3K/ AKT signaling, which led to attenuation of tumorigenesis via a tumor-specific increase in caspase-3-mediated apoptosis. Consistent with the mouse data, which suggest that ERBB3-ERBB4 heterodimers contribute to colon cancer survival, experimentally induced loss of ERBB3 in a KRAS mutant human colon cancer cell line was associated with loss of ERBB4 expression, and siRNA knockdown of either ERBB3 or ERBB4 resulted in elevated levels of apoptosis. These results indicate that the ERBB3 pseudo-kinase has essential roles in supporting intestinal tumorigenesis and suggest that ERBB3 may be a promising target for the treatment of colorectal cancers.

UR - http://www.scopus.com/inward/record.url?scp=70349199083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349199083&partnerID=8YFLogxK

U2 - 10.1172/JCI36435

DO - 10.1172/JCI36435

M3 - Article

C2 - 19690388

AN - SCOPUS:70349199083

VL - 119

SP - 2702

EP - 2713

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 9

ER -